Menu
With hundreds of scientists dedicated to new chemical entity (NCE) and new biologic entity (NBE) research, we have developed an enviable and robust pipeline of assets focused in oncology, immunology and pain. Our efforts are anchored in first- and best-in-class discovery. With a variety of NBEs and NCEs in various stages of clinical development, Glenmark is delivering on its commitment to bring the best science to patients worldwide.
Click here to view our innovative pipeline.
